The expression and correlation between circPRKCI and miR-545 in colorectal cancer
-
摘要:
目的 探讨结直肠癌组织环状RNA PRKCI(circPRKCI)、微小RNA-545(miR-545)的表达及其对预后的影响。 方法 收集2013年3月—2018年4月在郑州市第七人民医院行手术切除治疗的102例结直肠癌患者的癌组织和癌旁组织标本,分析circPRKCI、miR-545的表达与结直肠癌患者临床病理参数及预后的关系。 结果 与癌旁组织相比,circPRKCI在结直肠癌组织中的表达显著上调(1.47±0.69 vs. 0.82±0.42, t=8.644, P<0.05),miR-545在结直肠癌组织中的表达显著下调(0.86±0.55 vs. 1.60±0.66, t=8.908, P<0.05)。有淋巴结转移、TNM分期Ⅲ~Ⅳ期患者circPRKCI表达升高, miR-545表达下降(P < 0.05)。circPRKCI高表达、miR-545低表达患者的预后较差(P<0.05),circPRKCI和miR-545是结直肠癌患者预后不良的独立影响因素,两者表达呈负相关关系。 结论 circPRKCI、miR-545与结直肠癌患者的不良病理参数和预后相关,circPRKCI可能调控miR-545参与结直肠癌的进展。 -
关键词:
- 结直肠癌 /
- 微小RNA-545 /
- 环状RNA PRKCI /
- 临床病理参数
Abstract:Objective To investigate the expression of circular RNA PRKCI (circPRKCI) and microrNA-545 (miR-545) in colorectal cancer tissues and their effects on prognosis. Methods From March 2013 to April 2018, 102 patients with colorectal cancer underwent surgical resection in Zhengzhou Seventh People ' s Hospital were collected. The expression levels of circPRKCI and miR-545 in colorectal cancer patients with different clinicopathological characteristics were analyzed. The effects of circPRKCI and miR-545 expression levels on the prognosis of patients were analyzed by Cox regression and survival curve. Results The expression of circPRKCI was significantly up-regulated in colorectal cancer tissues compared to paracancer tissues (1.47±0.69 vs. 0.82±0.42, t=8.644, P < 0.05). Conversely, miR-545 expression was significantly down-regulated in colorectal cancer tissues (0.86±0.55 vs. 1.60±0.66, t=8.908, P < 0.05). The expression of circPRKCI increased and the expression of miR-545 decreased in patients with lymph node metastasis and TNM stage Ⅲ-Ⅳ (P < 0.05). Furthermore, patients with high expression of circPRKCI and low expression of miR-545 exhibited poor prognosis (P < 0.05). Both circPRKCI and miR-545 were identified as independent risk factors for poor prognosis in patients with colorectal cancer, and their expression showed a negative correlation. Conclusion The expression of circPRKCI and miR-545 is related to the adverse pathological parameters and prognosis in patients with colorectal cancer, suggesting a potential regulatory role of circPRKCI in the progression of colorectal cancer involving miR-545. -
Key words:
- Colorectal cancer /
- MicroRNA-545 /
- Circular RNA PRKCI /
- Clinicopathological parameters
-
表 1 结直肠癌组织和癌旁组织中circPRKCI、miR-545表达水平比较(x±s)
Table 1. Comparison of circPRKCI and miR-545 expression levels between colorectal cancer tissue and paracancer tissue
组别 例数 circPRKCI相对表达量 miR-545相对表达量 结直肠癌组织 102 1.47±0.69 0.86±0.55 癌旁组织 102 0.82±0.42 1.60±0.66 t值 8.644 8.908 P值 < 0.001 < 0.001 表 2 不同临床病理特征结直肠癌患者circPRKCI、miR-545表达水平比较
Table 2. Comparison of circPRKCI and miR-545 expression levels in colorectal cancer patients with different clinicopathological characteristics
项目 类别 例数 circPRKCI相对表达量(x±s) t值 P值 miR-545相对表达量[M(P25, P75)] Z值 P值 性别 男性 62 1.51±0.48 0.986 0.327 0.83(0.42, 1.18) 1.028 0.304 女性 40 1.41±0.53 0.85(0.57, 1.27) 年龄(岁) ≤60 32 1.43±0.51 0.625 0.533 0.84(0.61, 1.27) 0.494 0.621 >60 70 1.49±0.42 0.81(0.41, 1.31) 肿瘤直径(cm) ≤5 56 1.39±0.50 1.623 0.108 0.91(0.53, 1.28) 1.544 0.123 >5 46 1.57±0.62 0.78(0.28, 1.25) 淋巴结转移 有 55 1.62±0.48 3.085 0.003 0.81(0.28, 1.17) 2.756 0.006 无 47 1.29±0.60 0.94(0.70, 1.44) T分期 T1+T2 58 1.37±0.62 1.817 0.072 1.02(0.58, 1.36) 1.618 0.106 T3+T4 44 1.60±0.65 0.83(0.39, 1.22) TNM分期 Ⅰ~Ⅱ 55 1.33±0.49 2.924 0.004 1.01(0.54, 1.40) 2.642 0.008 Ⅲ~Ⅳ 47 1.62±0.51 0.73(0.30, 1.19) 表 3 不同circPRKCI、miR-545表达水平结直肠癌患者5年生存率比较
Table 3. Comparison of 5-year survival rates among colorectal cancer patients with different expression levels of circPRKCI and miR-545
组别 例数 5年生存[例(%)] log-rank χ2值 P值 circPRKCI高表达组 56 20(35.71) 6.713 0.010 circPRKCI低表达组 46 30(65.22) miR-545高表达组 40 24(60.00) 4.162 0.041 miR-545低表达组 62 26(41.94) 表 4 结直肠癌患者预后不良的影响因素分析
Table 4. Analysis of factors influencing poor prognosis in colorectal cancer patients
变量 β SE Waldχ2 P值 HR值 HR的95% CI 性别 0.141 0.085 2.734 0.098 1.151 0.974~1.361 年龄 0.201 0.128 2.483 0.115 1.223 0.952~1.570 肿瘤直径 0.710 0.412 2.966 0.085 2.034 0.907~4.563 淋巴结转移 0.972 0.348 7.806 0.005 2.642 1.337~5.227 T分期 0.772 0.412 3.507 0.061 2.164 0.965~4.855 TNM分期 1.145 0.419 7.475 0.006 3.143 1.383~7.141 circPRKCI表达 0.921 0.400 5.303 0.021 2.511 1.147~5.501 miR-545表达 -0.989 0.465 4.528 0.033 0.372 0.150~0.925 注:变量赋值如下,性别(男性=1,女性=0);年龄(≥60岁=1,<60岁=0);肿瘤直径(≥5 cm=1,<5 cm=0);淋巴结转移(有=1,无=0);T分期(T3+T4=1,T1+T2=0);TNM分期(Ⅲ~Ⅳ期=1,Ⅰ~Ⅱ期=0);circPRKCI表达(高表达=1,低表达=0);miR-545表达(高表达=1,低表达=0)。 -
[1] QIU H, CAO S, XU R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020[J]. Cancer Commun(Lond), 2021, 41(10): 1037-1048. [2] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005ZHENG R S, SUN K X, ZHANG S W, et al. Report of cancer epidemiology in China, 2015[J]. Chinese Journal of Oncology, 2019, 41(1): 19-28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005 [3] MILLER K D, NOGUEIRA L, DEVASIA T, et al. Cancer treatment and survivorship statistics, 2022[J]. CA Cancer J Clin, 2022, 72(5): 409-436. doi: 10.3322/caac.21731 [4] 李轩, 荣宝海, 解广东, 等. 环状RNA与结直肠癌相关性研究进展[J]. 中国中西医结合外科杂志, 2021, 27(1): 154-158. doi: 10.3969/j.issn.1007-6948.2021.01.031LI X, RONG B H, XIE G D, et al. Research progress of correlation between circular RNA and colorectal cancer[J]. Chinese Journal of Surgery of Integrated Traditional and Western Medicine, 2021, 27(1): 154-158. doi: 10.3969/j.issn.1007-6948.2021.01.031 [5] QIU M, XIA W, CHEN R, et al. The circular RNA circPRKCI promotes tumor growth in lung adenocarcinoma[J]. Cancer Res, 2018, 78(11): 2839-2851. doi: 10.1158/0008-5472.CAN-17-2808 [6] QI S X, SUN H, LIU H, et al. Role and mechanism of circ-PRKCI in hepatocellular carcinoma[J]. World J Gastroenterol, 2019, 25(16): 1964-1974. doi: 10.3748/wjg.v25.i16.1964 [7] WU L, LI Y, XU X M, et al. Circular RNA circ-PRKCI promotes cell proliferation and invasion by binding to microRNA-545 in gastric cancer[J]. Eur Rev Med Pharmacol Sci, 2019, 23(21): 9418-9426. [8] ZHANG X, YANG H, ZHAO L, et al. Circular RNA PRKCI promotes glioma cell progression by inhibiting microRNA-545[J]. Cell Death Dis, 2019, 10(8): 616. DOI: 10.1038/s41419-019-1863-z. [9] JIA X, LIU X, LI M, et al. Potential tumor suppressing role of microRNA-545 in epithelial ovarian cancer[J]. Oncol Lett, 2018, 15(5): 6386-6392. [10] CUI J, PAN G, HE Q, et al. MicroRNA-545 targets ZEB2 to inhibit the development of non-small cell lung cancer by inactivating Wnt/β-catenin pathway[J]. Oncol Lett, 2019, 18(3): 2931-2938. [11] HUANG X, LU S. MicroR-545 mediates colorectal cancer cells proliferation through up-regulating epidermal growth factor receptor expression in HOTAIR long non-coding RNA dependent[J]. Mol Cell Biochem, 2017, 431(1-2): 45-54. doi: 10.1007/s11010-017-2974-4 [12] 胡亚男, 王秋童, 何凤蝶, 等. 中国成人自报结直肠癌患者生活方式研究[J]. 中华全科医学, 2023, 21(2): 279-282. doi: 10.16766/j.cnki.issn.1674-4152.002864HU Y N, WANG Q T, HE F D, et al. Lifestyle study of Chinese adults with self-reported colorectal cancer[J]. Chinese Journal of General Practice, 2023, 21(2): 279-282. doi: 10.16766/j.cnki.issn.1674-4152.002864 [13] 郑磊, 路佳. 单细胞测序技术及其在结直肠癌中的应用[J]. 天津医药, 2021, 49(8): 891-896. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ202108023.htmZHENG L, LU J. Single cell sequencing and its application in colorectal cancer[J]. Tianjin Medical Journal, 2021, 49(8): 891-896. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ202108023.htm [14] KRISTENSEN L S, JAKOBSEN T, HAGER H, et al. The emerging roles of circRNAs in cancer and oncology[J]. Nat Rev Clin Oncol, 2022, 19(3): 188-206. doi: 10.1038/s41571-021-00585-y [15] MA Y, ZHANG D, WU H, et al. Circular RNA PRKCI silencing represses esophageal cancer progression and elevates cell radiosensitivity through regulating the miR-186-5p/PARP9 axis[J]. Life Sci, 2020, 259: 118168. DOI: 10.1016/j.lfs.2020.118168. [16] VERDUCI L, STRANO S, YARDEN Y, et al. The circRNA-microRNA code: emerging implications for cancer diagnosis and treatment[J]. Mol Oncol, 2019, 13(4): 669-680. doi: 10.1002/1878-0261.12468 [17] TO K K, TONG C W, WU M, et al. MicroRNAs in the prognosis and therapy of colorectal cancer: from bench to bedside[J]. World J Gastroenterol, 2018, 24(27): 2949-2973. doi: 10.3748/wjg.v24.i27.2949 -